Communiqués LivaNova PLC

Actions

LIVN

GB00BYMT0J19

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
75,44 ^USD	-2,23%		-3,02%	+22,61%

14/09	Livanova : un initié cède des actions pour une valeur de 273 032 dollars, selon un récent document de la SEC	MT
14/09	Transcript : LivaNova PLC Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 11:30 AM

Communiqués

23/09	LivaNova to Announce Third-Quarter 2026 Results	BU
03/09	LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September	BU
05/08	LivaNova : 2QFY 2026 Performance Presentation	PU
05/08	LivaNova: Q2 Earnings Snapshot	AQ
05/08	LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance	BU
24/06	LivaNova to Announce Second-Quarter 2026 Results	BU
16/06	LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea	BU
11/06	Jette Nygaard-Andersen Joins LivaNova Board as a New Director	BU
08/06	LivaNova Appoints Anne Liddy as Chief Legal Officer	AQ
05/06	LivaNova Appoints Anne Liddy as Chief Legal Officer	BU
21/05	LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit	BU
19/05	LivaNova to Present at Goldman Sachs Global Healthcare Conference in June	BU
06/05	LivaNova : 1QFY 2026 Performance Presentation	PU
06/05	LivaNova: Q1 Earnings Snapshot	AQ
06/05	LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance	BU
20/04	Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea	BU
25/03	LivaNova to Announce First-Quarter 2026 Results	BU
19/03	LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea	BU
25/02	LivaNova : 4QFY 2025 Performance Presentation	PU
25/02	LivaNova: Q4 Earnings Snapshot	AQ
25/02	LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance	BU
20/01	LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results	BU
23/12	LivaNova to Present at J.P. Morgan Healthcare Conference in January	BU
03/12	LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting	BU
02/12	LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea	BU